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Irritable bowel syndrome (IBS) is traditionally defined as a functional disorder – that is the presence of symptoms in the absence 
of demonstrable pathological abnormalities. In recent times, low grade inflammatory infiltrates in both the small and large bowel of 
some patients with IBS – often rich in mast cells, along with serological markers of low grade inflammation have focussed attention 
on IBS as an inflammatory disease. The observation that mast cells often lie in close association to enteric neurons, and in-vitro and   
in-vivo animal studies demonstrating that mast cell mediators may influence enteric motility provides a biologically plausible causal 
mechanism in IBS. Pilot studies on patients with IBS using the mast cell stabiliser sodium cromoglycate (‘proof of concept’) have 
been encouraging. The essential question remains why mast cells infiltrate the bowel of IBS patients. A disturbance of the ‘brain – 
gut axis’ is the current favoured hypothesis, whereby childhood stress or psychiatric comorbidity act via neuro-immune mechanisms 
to modulate low grade inflammation. An alternative hypothesis is that food allergy may be responsible. Serum specific IgE, and skin 
prick tests are not elevated in IBS patients, suggesting type 1 IgE mediated food allergy is not the cause. However questionnaire 
based studies indicate IBS patients have higher rates of atopic disease, and increased bronchial reactivity to methacholine has been 
demonstrated. In this review, we highlight the potential role of mast cells in IBS, and current and future research directions into this 
intriguing condition.
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Irritable bowel syndrome (IBS) is one of the most common 
gastrointestinal disorders and causes considerable morbidity 
amongst its sufferers [1]. Long defined as a functional 
gastrointestinal disorder (implying the lack of demonstrable 
pathological abnormalities) IBS is increasingly viewed as a low 
grade inflammatory disorder [2]. Both histological specimens 
obtained at endoscopy and serological cytokine studies have 
demonstrated low grade inflammation in IBS [3]. Mast cells (MC) 
appear to play a particularly important role, and pilot ‘intention 
to treat’ studies using MC stabilisers have yielded encouraging 
results [4]. The observation that mast cells often lie in close 
association to enteric neurons and in vitro and in vivo animal 
studies demonstrating that MC mediators may influence enteric 
motility provide a biologically plausible mechanism of causation 
in IBS [5].
Mast cells are normally found in the intestine, but why they apallergy.org
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may be found in higher density and, more importantly, why they 
are activated in patients with IBS has yet to be determined. One 
popular current hypothesis is that IBS represents a disturbance 
of the ‘brain-gut axis’ whereby stressful early life events and/or 
psychiatric co-morbidity mediate low level inflammation and 
mast cell infiltration of the bowel [3]. An alternative hypothesis 
is that food allergy may be responsible [6]. Traditional measures 
of type 1 IgE-mediated food allergy, such as serum specific 
IgE and RAST testing, are usually negative, but questionnaire-
based studies indicate an increased prevalence of atopic disease 
amongst IBS patients and bronchial provocation testing may be 
abnormal [7, 8]. In this review, the evidence for MC involvement 
in IBS is discussed, and the need for future collaborative research 
between gastroenterologists and allergist/immunologist alike is 
highlighted. 
IBS as an inflammatory condition
IBS is a common condition, with a prevalence of 10-20% being 
reported in Western countries, India, China and Japan [8]. Whilst 
not life-threatening, IBS causes considerable morbidity and is 
responsible considerable time off work and an impaired quality of 
life [9]. Female gender, a family history of IBS, a history of physical 
or sexual abuse and co-morbid psychiatric disorders are strong 
risk factors for IBS [10]. Indeed up to 70% of the patients referred 
to tertiary centres with IBS meet diagnostic criteria for anxiety or 
depression [10]. While this may represent a minority sub-group 
where uncontrolled symptoms may be the effect rather than the 
cause, such patients have focussed interest on the ‘brain-gut axis’ 
as the explanatory disease model [3].
IBS has traditionally been defined in terms of a symptom 
cluster and classed as a functional gastrointestinal disorder – 
implying an absence of demonstrable anatomical or histological 
pathology. The advent of gastrointestinal manometry and motility 
laboratories in the 1970’s lead to a focus on disturbances of 
motility and, later, to heightened sensitivity to luminal distension 
or ‘visceral hyperalgesia or hypersensitivity’ [11]. Many patients 
with IBS manifest abnormal colonic or small bowel motility (slow, 
fast or incoordinate) and/or hyperalgesia, but such physiological 
abnormalities have not found a place in routine clinical practice 
or in diagnosis or classification [11]. The pattern of symptoms 
remains the cornerstone of diagnosis and classification of 
functional gut disorders (the Rome III criteria as shown in Table 
1) [12]. For patients with IBS, they may then be classified IBS-C 
(constipation-predominant), IBS-D (diarrhoea-predominant) or 
IBS-A (alternating) according to their symptom pattern [12]. 
The observation that a percentage of patients who suffer from 
acute gastroenteritis go on to develop IBS renewed interest 
in IBS as an inflammatory condition [13]. Follow-up of these 
patients in multiple centres and cohorts has revealed a tendency 
to develop IBS-D and have low grade inflammatory infiltrates 
(often containing MCs) at endoscopy [3]. Subsequent endoscopic 
comparisons of patients with IBS-D who did not describe a pre-
existing acute infectious gastroenteritis found similar low grade 
inflammatory changes, allowing the ‘inflammatory hypothesis’ to 
be applied more generally [3].
Mast cell infiltrates in IBS
Many but not all human endoscopic biopsy studies of patients 
with IBS have found increased numbers of MCs in the luminal 
mucosa (Table 2) [14-19]. The density of MCs in both small and 
large bowel may be increased in patients with IBS, but the results 
are somewhat contradictory. Some studies demonstrate increased 
density in the small and not the large bowel and others vice-
versa. Increased density of MCs has been found in both male and 
female patients and in all subtypes of IBS. The presence of MCs per 
se does not necessarily imply they are pathogenically important 
unless they are activated. Indeed, Barbara et al demonstrated 
an increased number of degranulating MCs in patients with IBS 
compared to that in healthy controls [17]. Tryptase release from 
duodenal biopsies was elevated; arguably increased MC numbers 
should naturally cause increased tryptase following laboratory 
manipulation of biopsy specimens. 
There have been some attempts to correlate the density of 
MCs to clinical symptoms [17]. Several studies have shown 
Table 1. Rome III diagnostic criteria for irritable bowel syndrome
At least 3 months, with onset at least 6 months previously of recurrent abdominal pain or discomfort* associated with 2 or more of the following: 
• Improvement with defecation; and/or 
• Onset associated with a change in frequency of stool; and/or 
• Onset associated with a change in form (appearance) of stool 
*Discomfort means an uncomfortable sensation not described as pain.apallergy.org
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an association with the severity of abdominal pain [5, 17]. 
Two groups have examined the associations with psychiatric 
co-morbidity, particularly anxiety and depression which are 
commonly described in IBS [14, 15]. In only one was the density 
of MCs in the intestine significantly correlated with the severity of 
anxiety and depression [15] .
A rationale for mast cells as a causative factor for IBS 
symptomatology
There are several layers of evidence in support of a major role of 
MCs in the genesis of symptoms in IBS.
•	 	 MCs are present in the appropriate microenvironment of the 
gastrointestinal tract. They are found in both the mucosa 
and serosal layers and express high affinity (FcRγ) receptors 
to IgE [3]. MCs in humans lie in close proximity to neural 
endings and may form membrane-membrane interactions 
[20]. The factors regulating the close apposition of MCs to 
enteric neural cells are incompletely understood, but may 
involve a two-way communication by which MCs produce 
neurotrophic growth factors, and MCs are in turn attracted 
by neuropeptides Further research into this complex inter-
play is clearly needed if the ‘brain-gut’ axis is to be under-
stood (see above) [21].
•	 	 Mediators released from MCs are capable of inducing 
sensorimotor dysfunction. Degranulation of MCs is 
associated with release of mediators such as histamine, 
tryptase and prostaglandins which may influence 
enteric efferents via proteinase-activated receptors [22]. 
Furthermore, a study using mucosal mediators of IBS 
patients on rat jejunal sensory nerve firing found that the 
stimulatory effect of the mucosal mediators released from 
the mucosal biopsies of IBS patients could be inhibited by 
histamine receptor blockade [5]. 
•	 	 MC activation may cause abdominal symptoms consistent 
with IBS. Patients with clear IgE-mediated allergic reactions 
to food often complain of functional abdominal symptoms 
[23]. More strikingly, patients with systemic mastocytosis 
who have an enteric infiltrate often complain of a pattern of 
abdominal symptoms that fulfil criteria for IBS [24].
•	 	 Apparent efficacy of treatments aimed at decreasing MC 
mediator release and/or infiltration. Sodium cromoglycate 
is classified as a ‘mast cell stabiliser’ and has shown promise 
in pilot ‘proof-of-concept’ studies to improve the symptoms 
of IBS patients [25]. The oral anti-inflammatory 5ASA has 
been found in one small randomised controlled study 
to decrease the symptoms of IBS, and this corresponded 
with a decrease in the density of the MC infiltrate within 
the colon. Furthermore the mast cell stabiliser and 
antihistamine (H-1 receptor blocker) ketotifen was found 
to decrease the symptoms of IBS in a recent placebo 
controlled trial involving 60 patients (30 in each arm) [26]. 
Curiously, the patients who received ketotifen and improved 
symptomatically at 8 weeks were not less likely than controls 
to manifest mast cell degranulation (as defined by tryptase 
or histamine release on endoscopic biopsy specimens) 
and the intestinal infiltration of mast cells was unchanged 
following the treatment course [26]. This led the authors 
to suggest that H-1 receptor blockade, and not mast cell 
stabilisation was the likely therapeutic mechanism [26]. 
Cleary further research is required.
IBS and the brain-gut axis
As outlined above, the term ‘brain-gut axis’ refers to the bi-direc-
tional communication between the gut (enteric nervous system, 
luminal wall) and the central nervous system (including the hy-
pothalamopituitary axis) [27]. More recently, the complex neuro-
immune interactions between the intestinal microflora and the 
host has been incorporated into this model (Fig. 1). The brain-gut-
axis model attempts to explain the complex interplay of factors 
potentially responsible for the precipitation and perpetuation of 
Table 2. Studies of intestinal mast cell infiltration in irritable bowel syndrome
Reference No. of IBS No. of control Duodenum Jejunum Ileum Colon Significance
[14] 48 24 N/A N/A N/A + yes
[15] 50 21 N/A N/A N/A + yes
[16] 41 48 + N/A N/A N/A yes
[17] 44 22 N/A N/A N/A + yes
[18] 20 14 N/A + N/A N/A yes
[19] 42 12 N/A N/A N/A + yesapallergy.org
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IBS and other gastrointestinal conditions. Animal studies have 
shown that maternal deprivation may result in later sensitivity 
to manometric gastrointestinal stimuli, whilst stressing an adult 
rodent can result in increased cortisol releasing hormone (CRH), 
and colonic MC infiltration and degranulation [28]. The interplay 
between stress and the disturbed gastrointestinal motility and 
sensory function is particularly pertinent given the association 
between childhood physical and sexual abuse, psychiatric illness, 
life stress and IBS. Indeed, human studies reveal abnormal colonic 
motility mimicking IBS in subjects injected with CRH [29]. 
The intestinal microbiota may play an additional modulating 
role in the brain-gut axis and are the subject of current intense 
research interest. It is not known why some patients with 
IBS demonstrate abnormalities in their microbiota, but it is 
proposed that the spectrum of flora in these patients favours a 
pro-inflammatory mucosal reaction [30]. Encouragingly, a few 
studies suggest a role for probiotics in successfully alleviating the 
symptoms of IBS [30]. 
IBS and food allergy 
Patients frequently attribute their symptoms to food intake and 
there is little doubt that food is an important trigger for those 
symptoms [23]. There are many mechanisms by which this can 
occur and these include luminal distension and osmotic effects, 
direct stimulation of the MCs or enteric nervous system by 
bioactive chemicals such as salicylates, and food hypersensitivity 
(non-IgE-mediated) reactions [31]. However, there is no direct 
evidence to suggest that classical IgE mediated type 1 allergic 
reactions to food antigens play a role in the symptoms of IBS [23]. 
Skin prick and serum specific IgE antibody testing to common 
food antigens are generally identical to healthy controls [31]. 
Few studies have examined responses to foods in the gut-
associated immune compartment, which may be very different 
to those in the systemic immune compartment. One approach is 
to perform the equivalent of skin prick tests via the colonoscope 
and to look for wheal reactions after the mucosal injection of food 
antigens. This test, the colonoscopic allergen provocation test 
(COLAP), showed positive responses to specific food antigens in 
a significant majority of patients with functional gut symptoms 
GUT:
autonomic dysfunction
                   +
low grade in￿amation
BRAIN:
autonomic dysfunction
                   +
psychomatic comorbidity
microbiota
food antigens
histamine
tryptase
IBS
CRH
Mast cell:
activation
In￿ammatory
Cytokines
Fig. 1. The Brain – Gut axis in irritable bowel syndrome (IBS).apallergy.org
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and suspected food hypersensitivity who had normal skin prick 
and serum specific IgE to common food antigens [32]. Hence it is 
conceivable that a percentage of IBS patients have an IgE or other 
immune-mediated food hypersensitivity that is being ‘missed’. 
There have been no subsequent reports of the further application 
of the COLAP test or on findings in patients with IBS. This deserves 
further study.
IgG antibodies to common food antigens may be detected 
in the serum of healthy children and adults [6]. Patients with 
IBS have elevated titres of these antibodies in some studies, 
although no correlation between the degree of elevation in 
IgG and the severity of the symptoms has been demonstrated 
[33, 34]. A randomised controlled trial involving only patients 
with IBS who were allocated either a sham diet or elimination 
diet to culprit foods to which the IgG antibodies were elevated 
demonstrated symptomatic benefit at 12 weeks, but only after 
data were corrected for adherence [6]. Healthy controls were not 
included in this study and IgG antibodies were not measured at 
the conclusion of the study. Sustained benefit from this food-
specific IgG approach has been claimed by another group, 
but the concurrent use of probiotics reduced the clarity of 
the findings [34]. Further studies are warranted. Until a cause-
effect relationship is clearly established, the quantitative (and 
not qualitative difference) in serum IgG to food antigens could 
conceivably be an epiphenomenon, perhaps related to an 
inflamed or ‘leaky’ gut [35].
IBS and atopic diseases
IBS patients are no more likely than the background population 
to record positive skin prick or serum specific IgE tests to common 
environmental antigens. Curiously however, there is an increased 
prevalence of IBS amongst patients with other ‘atopic’ conditions, 
according to some studies [7]. For example, an association was 
found between allergy patients attending a tertiary hospital clinic 
and a high proportion of IBS symptoms meeting Rome criteria 
using a self-report questionnaire [7]. In a retrospective case 
control study of more than 7,000 patients attending a general 
practise setting in the UK, an increased prevalence of allergic 
rhinitis and asthma amongst patients with lower gastrointestinal 
symptoms was reported [36]. It should be pointed out that 
questionnaire-based studies potentially introduce responder bias; 
IBS patients may, for example, display a ‘learned illness’ behaviour 
and be expected to complain of symptoms without organic 
cause. Several more objective papers have linked asthma with 
IBS and have demonstrated increased airway responsiveness to 
inhaled methacholine and/or reversibility with bronchodilators 
in IBS patients who do not give a history of asthma or other 
atopic conditions [8]. In a study of 133 IBS patients and matched 
healthy controls, asthma was diagnosed in 15% of the IBS group 
compared to 1.5% of controls [8]. By contrast, another group 
failed to demonstrate an increased prevalence of asthma amongst 
IBS patients in a study of 42 IBS patients and 42 matched healthy 
controls [37].
Hence it would appear that the association between IBS and 
atopic conditions is controversial, and that traditional measures 
of ‘atopy’ are negative [7]. Rather the association is based on 
self reported symptom clusters and/or the objective finding of 
bronchial hyper-reactivity. As many cases of asthma, particularly 
of adult onset are apparently unrelated to allergy, other shared 
cofactors may be responsible for the association, including 
alterations in sympathetic/ parasympathetic tone [38]. Further 
study is needed, perhaps examining the mucosa of both the 
bronchi and gut of the putative ‘asthmatic’ IBS subgroup, and 
correlating the IBS symptoms with respiratory function tests over 
time. 
Stress as a precipitating factor for food allergy – towards a 
unifying conceptual framework with treatment implications
Two opposing models of IBS causation have been outlined: 
•	 	 The ‘head-down’ hypothesis: psychological or physical stress 
activates the hypothalamic-pituitary axis, central and enteric 
nervous system to release CRH and neuropeptides to attract 
MCs to the bowel wall [39]; and
•	 	 The ‘bottom-up’ hypothesis: Food allergens/antigens incite 
the inflammatory infiltrate [7]. 
There is no reason why both forces can’t be operating (Fig. 1). 
This is supported by studies of patients with post-infectious IBS, 
in which patients with a history of physical or sexual abuse or 
depression (head-down) are more likely to develop IBS following 
a self limited episode of acute infectious diarrhoea (bottom-up) 
[13, 40].
Animal models provide a clue as to how stress may ‘prime’ a 
patient to develop a localised inflammatory response to food 
antigens. Rats that were subjected to stress prior to consumption 
of a labelled oral antigen (horse-radish peroxidase - HRP) were not 
only more likely to absorb the HRP, but also more likely to form 
circulating HRP-specific IgE and develop a denser inflammatory 
infiltrate containing MCs in the intestinal wall [28]. While this apallergy.org
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model is not directly applicable to IBS in humans in that these 
patients have a normal serum IgE to food antigens, the concept 
of stress modulating intestinal permeability, antigen presentation 
and inflammatory cell recruitment may guide future research. 
Promising avenues of inquiry may include the study of toll-like 
receptors on enterocytes as well as cytokine and microarray 
analysis.
Recent advances in dietary therapy directed at food intolerance 
(specifically short-chain poorly absorbed carbohydrates) 
have improved the ability to achieve symptomatic control 
in the majority of patients with IBS, but this therapy is purely 
symptomatic and does not address the potential causes 
of IBS [41]. In light of the above unifying hypothesis, more 
pathogenically-related therapy can be proposed. Potential ‘head-
down’ therapies such as the use of antidepressant medication, 
hypnotherapy and cognitive behavioural therapy, which show 
benefit in some patients, may be combined with ‘bottom-up’ 
therapies such as excluding validly identified food antigens form 
the diet or pharmacological agents such as mast cell stabilisers, 
antihistamines and mesalazine, which also have some evidence 
for efficacy [1, 25]. Thus, a dualistic treatment approach based 
upon the unifying hypothesis may improve therapy in the future 
(Fig. 2).
Summary
IBS is one of the most common gastroenterological disorders, 
yet its aetiology remains elusive. Recent interest has focussed 
on low grade inflammation, particularly involving MCs in its 
pathogenesis. The most compelling overall hypothesis to explain 
the MC infiltrate is of a disturbance of the brain-gut axis, whereby 
MCs may be attracted to the bowel via neuropeptides – although 
only animal models support this assertion. While current evidence 
suggests type 1 IgE-mediated food allergy is an unlikely cause 
of the MC infiltrate, patients with IBS appear to describe more 
frequent atopic symptoms and studies of the gut immune 
compartment have produced some signals that immune-
mediated reactions to food antigens may indeed be causally 
related to symptom genesis. Cleary, IBS represents a fertile soil for 
research for both gastroenterologists and allergy/immunologists 
alike.
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